Skip to main content

Advertisement

SpringerLink
Log in

B-Cell Receptor Pathobiology and Targeting in NHL

  • Lymphomas (PA Hamlin, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

B-cell receptor signaling plays varied and critical roles in B-cell development, homeostasis and disease. The key players of the pathway and its many signaling modulators have been identified as well as some of the mechanisms by which the pathway is regulated. With the increased incidence of non-Hodgkin’s lymphoma in recent years, there is a clear clinical need for novel agents to offer new options in resistant disease to potentially improve outcomes in curative settings. With the tremendous insight gained in the last 2 decades from basic science research, our understanding of the pathobiology of the B-cell receptor is leading to the discovery and clinical development of many new therapeutic targets such as Syk, Bruton’s tyrosine kinase, and phosphatidylinositol 3-kinase. This review will emphasize contemporary and salient findings on novel agents targeting the B-cell receptor signaling pathway for the treatment of non-Hodgkin’s lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011.

  2. Young RM, Hardy IR, Clarke RL, et al. Mouse models of non-Hodgkin Lymphoma reveal syk as an important therapeutic target. Blood. 2009;113:2508–16.

    Article  PubMed  CAS  Google Scholar 

  3. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417–29.

    Article  PubMed  CAS  Google Scholar 

  4. Ysebaert L, Morschhauser F. Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies. Expert Opin Investig Drugs. 2011;20:1167–74.

    Article  PubMed  CAS  Google Scholar 

  5. Jumaa H, Hendriks RW, Reth M. B-cell signaling and tumorigenesis. Annu Rev Immunol. 2005;23:415–45.

    Article  PubMed  CAS  Google Scholar 

  6. Minegishi Y, Coustan-Smith E, Rapalus L, et al. Mutations in Igalpha (CD79a) result in a complete block in B-cell development. J Clin Invest. 1999;104:1115–21.

    Article  PubMed  CAS  Google Scholar 

  7. Hombach J, Tsubata T, Leclercq L, et al. Molecular components of the B-cell antigen receptor complex of the IgM class. Nature. 1990;343:760–2.

    Article  PubMed  CAS  Google Scholar 

  8. Kraus M, Pao LI, Reichlin A, et al. Interference with immunoglobulin (Ig)α immunoreceptor tyrosine-based activation motif (ITAM) phosphorylation modulates or blocks B cell development, depending on the availability of an igbeta cytoplasmic tail. J Exp Med. 2001;194:455–69.

    Article  PubMed  CAS  Google Scholar 

  9. Bannish G, Fuentes-Panana EM, Cambier JC, et al. Ligand-independent signaling functions for the B lymphocyte antigen receptor and their role in positive selection during B lymphopoiesis. J Exp Med. 2001;194:1583–96.

    Article  PubMed  CAS  Google Scholar 

  10. Reichlin A, Hu Y, Meffre E, et al. B cell development is arrested at the immature B cell stage in mice carrying a mutation in the cytoplasmic domain of immunoglobulin beta. J Exp Med. 2001;193:13–23.

    Article  PubMed  CAS  Google Scholar 

  11. Clark MR, Tanaka A, Powers SE, et al. Receptors, subcellular compartments and the regulation of peripheral B cell responses: the illuminating state of energy. Mol Immunol. 2010;48:1281–6.

    Article  PubMed  Google Scholar 

  12. • Turner M, Mee PJ, Costello PS, et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature. 1995;378:298–302. Syk is essential to couple the BCR to distal signal transduction elements.

    Article  PubMed  CAS  Google Scholar 

  13. • Cheng AM, Rowley B, Pao W, et al. Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 1995;378:303–6. Syk has a critical role in maintaining vascular integrity, promoting differentiation and clonal expansion of B-lineage cells.

    Article  PubMed  CAS  Google Scholar 

  14. Khan WN, Sideras P, Rosen FS, et al. The role of bruton’s tyrosine kinase in B-cell development and function in mice and man. Ann NY Acad Sci. 1995;764:27–38.

    Article  PubMed  CAS  Google Scholar 

  15. Nishizumi H, Taniuchi I, Yamanashi Y, et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity. 1995;3:549–60.

    Article  PubMed  CAS  Google Scholar 

  16. Rolli V, Gallwitz M, Wossning T, et al. Amplification of B cell antigen receptor signaling by a Syk/itam positive feedback loop. Mol Cell. 2002;10:1057–69.

    Article  PubMed  CAS  Google Scholar 

  17. Cornall RJ, Goodnow CC, Cyster JG. Regulation of B cell antigen receptor signaling by the lyn/cd22/shp1 pathway. Curr Top Microbiol Immunol. 1999;244:57–68.

    Article  PubMed  CAS  Google Scholar 

  18. • Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of bruton’s tyrosine kinase in immunodeficient XID mice. Science. 1993;261:358–61. A single conserved residue within the amino terminal unique region of Btk was mutated and found to interfere with normal B cell signaling demonstrating the importance of Btk protein interaction, a rationale for targeting Btk in B-cell malignancies.

    Article  PubMed  CAS  Google Scholar 

  19. Takata M, Kurosaki T. A role for Bruton’s tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma. J Exp Med. 1996;184:31–40.

    Article  PubMed  CAS  Google Scholar 

  20. Ishiai M, Kurosaki M, Pappu R, et al. BLNK required for coupling Syk to PLC gamma 2 and rac1-jnk in B cells. Immunity. 1999;10:117–25.

    Article  PubMed  CAS  Google Scholar 

  21. Kurosaki T, Tsukada S. BLNK: connecting Syk and Btk to calcium signals. Immunity. 2000;12:1–5.

    Article  PubMed  CAS  Google Scholar 

  22. Saijo K, Mecklenbrauker I, Santana A, et al. Protein kinase C beta controls NFkB activation in B cells through selective regulation of the IkB kinase alpha. J Exp Med. 2002;195:1647–52.

    Article  PubMed  CAS  Google Scholar 

  23. Argyriou P, Economopoulou P, Sotirios P. The role of mTOR inhibitors for the treatment of B-cell lymphomas. Adv Hematol. 2012;2012:435342.

    PubMed  Google Scholar 

  24. Leseux L, Hamdi SM, Saati TA, et al. Syk-dependent motor activation in follicular lymphoma cells. Blood. 2006;108:4156–62.

    Article  PubMed  CAS  Google Scholar 

  25. Contri A, Brunati AM, Trentin L, et al. Chronic lymphocytic leukemia B cells contain anomalous lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest. 2005;115:369–78.

    PubMed  CAS  Google Scholar 

  26. •• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11. By gene-expression profiling, tumor, and normal cell analyses, identified two distinct subtypes, an activated B cell-like DLBCL known as ABC subtype, and a germinal centre B-cell DLBCL, patients of which had a significantly better overall survival compared with the ABC genetic signature.

    Article  PubMed  CAS  Google Scholar 

  27. Yang C, Lu P, Lee FY, et al. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia. 2008;22:1755–66.

    Article  PubMed  CAS  Google Scholar 

  28. • Chen L, Monti S, Juszczynski P, et al. SyK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111:2230–7. Using DLBCL cell lines and primary tumors the important role of Syk in driving survival signals in DLBCL is demonstrated and as a potential target using fostamatinib, a Syk inhibitor.

    Article  PubMed  CAS  Google Scholar 

  29. Rinaldi A, Kwee I, Taborelli M, et al. Geneomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006;132:303–16.

    Article  PubMed  CAS  Google Scholar 

  30. Friedberg J, Sharman J, Schaefer-Cutillo J, et al. Fostamatinib disodium, an oral inhibitor of Syk, is well tolerated and has significant clinical activity in diffuse large B-cell lymphoma and chronic lymphocytic leukaemia. Blood. 2008;112:Abstract 3.

  31. Pollyea DA, Smith S, Fowler N, et al. A phase I dose escalation study of the Btk inhibitor pci-32765 in relapsed and refractory B cell non-Hodgkin lymphoma and use of a novel fluorescent probe pharmacodynamic assay [Abstract]. Blood. 2009;114:3713.

    Google Scholar 

  32. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. PNAS. 2010;107:13075–80.

    Article  PubMed  CAS  Google Scholar 

  33. Walsh KJ, Fan S, Patel A, et al. PI3K inhibitors inhibit lymphoma growth by downregulation of MYC-dependent proliferation. Blood. 2011;114:1697.

    Google Scholar 

  34. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.

    Article  PubMed  CAS  Google Scholar 

  35. Vogt PK, Kang S, Elsliger MA, et al. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci. 2007;32:342–9.

    Article  PubMed  CAS  Google Scholar 

  36. Abubaker J, Bavi PP, Al-harbi S, et al. PIK3CA mutations are mutually exclusive with pten loss in diffuse large B-cell lymphoma. Leukemia. 2007;21:2368–70.

    Article  PubMed  CAS  Google Scholar 

  37. Herman SEM, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116:2078–88.

    Article  PubMed  CAS  Google Scholar 

  38. Furman RR, Byrd JC, Brown JR, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase (PIK3) delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Program and abstracts of the 52nd American Society of Hematology Annual Meeting and Exposition. 2010; Orlando, Florida. [Abstract 55].

  39. • Lannutti BJ, Meadows SA, Kashishian A, et al. CAL-101, an oral p110δ selective phosphatidylinositol-3-kinase (PI3K) inhibitor for the treatment of B cell malignancies inhibits PI3K signaling, cellular viability and protective signals of the microenvironment. Blood. 2009;114:286. These data demonstrate the important of PI3K isoform-δ in regulating BCR signaling in malignant B-cells as well as the microenvironment thereby providing the rationale for the clinical development of isoform-δ inhibitors of PI3K alone or in combination for patients with hematologic malignancies.

    Google Scholar 

  40. Friedberg J, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578–85.

    Article  PubMed  CAS  Google Scholar 

  41. Coutre SE, Byrd JC, Furman RR, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2011;29:6631.

    Google Scholar 

  42. Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood. 2010;116:1777.

    Google Scholar 

  43. Kahl BS, Longo WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Oxf J. 2006;17:1418–12.

    CAS  Google Scholar 

  44. Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical endpoints in chronic lymphocytic leukemia. J Clin Oncol. 2012. doi:10.1200/JCO.2012.43.3748.

  45. O’Brien S, Burger JA, Blum K, et al. The Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase IB/II study. Blood. 2011;118:983.

    Google Scholar 

  46. Wang L, Martin P, Blum KA, et al. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood. 2011;118:442.

    Google Scholar 

  47. Byrd JC, Furman RR, Coutre SE, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients PTS): interim results of a phase Ib/II study. J Clin Oncol. 2012;30:6507.

    Google Scholar 

  48. Smith MR, Neuberg D, Flinn IW, et al. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood. 2011;118:3525–7.

    Article  PubMed  CAS  Google Scholar 

  49. Sharman J, de Vos S, Leonard JP, et al. A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood. 2011;118:1787.

    Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN, 37203, USA

    Ines M. Macias-Perez

  2. The Sarah Cannon Research Institute, 250 25th Avenue, Suite 412, Nashville, TN, 37203, USA

    Ian W. Flinn

Authors
  1. Ines M. Macias-Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian W. Flinn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian W. Flinn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Macias-Perez, I.M., Flinn, I.W. B-Cell Receptor Pathobiology and Targeting in NHL. Curr Oncol Rep 14, 411–418 (2012). https://doi.org/10.1007/s11912-012-0254-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-012-0254-8

Keywords

Search

Navigation